ADAnna V. Dubinina

Anna V. Dubinina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna V. Dubinina has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antithrombotic therapy in coronary artery disease: strategy choice based on comorbidity. A review

    by Olga D. Ostroumova, Aleksey I. Kochetkov, Anna V. Dubinina, Svetlana S. Telkova, Natalia E. Gavrilova, Nicolai M. Doldo, Elena V. Mironova

    Coronary artery disease (CAD) remains a leading cause of mortality, and its frequent coexistence with atrial fibrillation (AF) significantly worsens prognosis, presenting physicians with a complex choice between stroke prevention, protection from coronary events, and minimization of bleeding risk. Even in patients with stable CAD, a high residual risk of thrombotic complications persists, driven by ongoing activation of the coagulation cascade, which traditional antiplatelet monotherapy cannot fully control. The strategy of dual pathway inhibition of thrombus formation has improved treatment outcomes: adding rivaroxaban at a "vascular" dose of 2.5 mg twice daily to acetylsalicylic acid provides a significant reduction in the risk of cardiovascular death and ischemic events with an acceptable safety profile. This approach is justified in patients at high ischemic risk, particularly those with a history of myocardial infarction or multivessel CAD. In the presence of AF, the principles of antithrombotic protection fundamentally change, mandating the inclusion of full-dose anticoagulation. The key strategy to address this challenge is treatment de-escalation: from the shortest possible courses of triple therapy (anticoagulant plus two antiplatelet agents) in the acute phase after percutaneous coronary intervention to dual therapy (anticoagulant plus clopidogrel) during the first year of follow-up. In the long term, stable patients benefit from a transition to anticoagulant monotherapy, which is non-inferior to combination therapy in preventing thrombotic events and significantly superior in terms of safety, as confirmed by large clinical trials and meta-analyses. Thus, rivaroxaban possesses the most comprehensive evidence base among direct oral anticoagulants, covering the entire spectrum of clinical scenarios, from secondary prevention in isolated CAD to the management of patients with concomitant AF. This enables a truly individualized approach, carefully balancing ischemic and bleeding risks in real-world clinical practice.

  • Open Access

    Atrial fibrillation and multimorbidity: How to choose the perfect direct oral anticoagulant?

    by O. D. Ostroumova, A. V. Dubinina, S. S. Telkova, A. I. Kochetkov, N. E. Gavrilova, E. Yu. Ebzeeva, A. V. Arablinskiy, O. A. Milovanova

    Atrial fibrillation is one of the most common tachyarrhythmias, the prevalence of which is steadily increasing due to an increase in the proportion of the elderly population. The presence of a comorbidities in elderly patients with atrial fibrillation, increasing the risk of thromboembolic events, has a significant impact on the clinical strategy of atrial fibrillation, as well as on the choice of therapeutic tactics, especially anticoagulant therapy with proven efficacy and low risk of bleeding. One of the most common concomitant diseases in patients with atrial fibrillation are chronic kidney disease, anemia and coronary artery disease. These comorbidities in patients with atrial fibrillation not only increase the risk of stroke and/or systemic embolism, but are also accompanied by an increased risk of cardiovascular mortality, all causes mortality, and hemorrhagic events. At the same time, according to research data, about half of polymorbid patients with atrial fibrillation do not receive anticoagulant therapy, which indicates a low awareness of physicians about rational pharmacotherapy based on clinical recommendations for this cohort of patients. The drug of choice with the most studied safety profile and a high degree of efficacy in these patients is apixaban from the group of direct oral anticoagulants. Unlike vitamin K antagonists and other representatives of direct oral anticoagulants, apixaban, according to the conducted studies, is associated with a more significant reduction in the risk of thromboembolic events, and most importantly, has a lesser effect on the risks of bleeding in patients, predisposing to hemorrhagic complications, with atrial fibrillationand concomitant coronary artery disease, anemia, chronic kidney disease.

  • Open Access

    Anxiety and sleep disorders in general practice

    by O. A. Polyakova, E. Yu. Ebzeeva, A. V. Dubinina, S. S. Telkova, A. V. Asoskova, L. D. Kozgunova, O. D. Ostroumova

    Anxiety and sleep disorders are an urgent problem of modern healthcare, which should be treated at the earliest possible stages, since this would prevent the development of a wide range of complications of these conditions. At the same time, given the bidirectional relationship between anxiety and sleep disorders, the search and development of safe and effective remedies for their correction is becoming increasingly relevant. The prescription of a set of measures of nonmedicamental and medicamental nature is considered to be the main methods of therapy for anxiety and sleep disorders. This article presents diagnostic tools that allow the general practitioner to identify anxiety and sleep disorders (insomnia) in a patient as early as possible, and discusses the therapeutic strategies for using a combination of glycine and melatonin in appropriate patients.

  • Modern view on treatment of iron and folic acid deficiency

    by A.I. Martynov, E.A. Lukina, A.G. Malyavin, O.D. Ostroumova, E.V. Shikh, M.V. Klepikova, S.S. Telkova, A.V. Dubinina

    Iron plays a key role in maintaining metabolic processes, energy exchange, respiration, immunobiological and oxidation-reduction reactions. Deficiency of this micronutrient is the most common nutrient deficiency worldwide and a cause of anemia in a large part of the population. The risk group includes women, especially during pregnancy, children and the elderly. Reduced intake of another significant micronutrient, folic acid, burdens the already existing iron-deficiency anemia (IDA) or acts as an independent disease. Due to the high prevalence of iron deficiency and IDA, the problem of development and optimization of the most effective and safe treatment remains relevant. As a result of this, on 22 of March, 2023 yr. a round table conference «Modern view on the treatment of iron and folic acid deficiency» was held under the moderation of A.G. Malyavin with the participation of speakers, who are key experts in this sphere. During the round table, the issue of balance between effective treatment of iron deficiency condition and high tolerability of iron supplements was discussed, and effective ways of treatment were proposed. In this connection, such aspects as iron metabolism in the different conditions, criteria for the iron deficiency, folates and IDA diagnosis, are examined in detail in the present review. Special attention is paid to the issues of low-dose oral forms of iron supplements application for the prevention and treatment of iron deficiency conditions, either with folate deficiency or without.